On 23 May the 79th World Health Assembly adopted the Global Action Plan on antimicrobial resistance (GAP-AMR) 2026-2036, targeting a 10% reduction in deaths from bacterial AMR by 2030 under a One Health framework1. antimicrobial resistance is the process by which bacteria evolve to survive the drugs meant to kill them, slowly emptying the antibiotic toolbox; One Health means an integrated approach spanning human, animal and environmental health, where most antibiotics are actually consumed.
Bacterial AMR was associated with 4.71 million deaths in 2021, and the trajectory points to a projected 39 million deaths a year by 20502. AMR kills more people annually than HIV or malaria, yet draws a fraction of the attention because the deaths are diffuse and recorded against the underlying infection rather than the resistance. A binding 2030 figure matters because it is the first concrete number a government can be measured against; previous AMR declarations set direction without a yardstick.
The target only works if the laboratories exist to read it. Most of the worst-affected regions cannot routinely test which infections are resistant, so a mortality goal floats free of the data needed to verify it. That gap is what ARILAC, the Africa CDC resistance-testing laboratory network launched on 6 May, is built to close. The plan and the lab network are the same project seen from two ends: a benchmark set in Geneva and the capacity to measure it being assembled in Addis Ababa. In a week dominated by a misfiring Ebola response, it is the one piece of multilateral machinery that finished its work.
